PMID- 24481662
OWN - NLM
STAT- MEDLINE
DCOM- 20140819
LR  - 20211021
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 35
IP  - 6
DP  - 2014 Jun
TI  - EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in 
      patients with osteosarcoma.
PG  - 5159-65
LID - 10.1007/s13277-014-1668-8 [doi]
AB  - Several studies have focused on the relationships between the expression of 
      extracellular matrix metalloproteinase inducer (EMMPRIN) and the prognosis of 
      patients with malignant tumors. However, few of these have investigated the 
      expression of EMMPRIN in osteosarcoma. We examined expression levels of EMMPRIN 
      immunohistochemically in 53 cases of high-grade osteosarcoma of the extremities 
      and analyzed the correlation of its expression with patient prognosis. The 
      correlation between matrix metalloproteinases (MMPs) and EMMPRIN expression and 
      the prognostic value of co-expression were also analyzed. Staining positivity for 
      EMMPRIN was negative in 7 cases, low in 17, moderate in 19, and strong in 10. The 
      overall and disease-free survivals (OS and DFS) in patients with higher EMMPRIN 
      expression (strong-moderate) were significantly lower than those in the lower 
      (weak-negative) group (0.037 and 0.024, respectively). In multivariate analysis, 
      age (P=0.004), location (P=0.046), and EMMPRIN expression (P=0.038) were 
      significant prognostic factors for overall survival. EMMPRIN expression (P=0.024) 
      was also a significant prognostic factor for disease-free survival. Co-expression 
      analyses of EMMPRIN and MMPs revealed that strong co-expression of EMMPRIN and 
      membrane-type 1 (MT1)-MMP had a poor prognostic value (P=0.056 for DFS, P=0.006 
      for OS). EMMPRIN expression and co-expression with MMPs well predict the 
      prognosis of patients with extremity osteosarcoma, making EMMPRIN a possible 
      therapeutic target in these patients.
FAU - Futamura, Naohisa
AU  - Futamura N
AD  - Department of Orthopaedic Surgery, Nagoya University Graduate School and School 
      of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
FAU - Nishida, Yoshihiro
AU  - Nishida Y
FAU - Urakawa, Hiroshi
AU  - Urakawa H
FAU - Kozawa, Eiji
AU  - Kozawa E
FAU - Ikuta, Kunihiro
AU  - Ikuta K
FAU - Hamada, Shunsuke
AU  - Hamada S
FAU - Ishiguro, Naoki
AU  - Ishiguro N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140131
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (BSG protein, human)
RN  - 136894-56-9 (Basigin)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EC 3.4.24.80 (Matrix Metalloproteinase 14)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Basigin/*analysis
MH  - Bone Neoplasms/chemistry/*mortality
MH  - Cell Line, Tumor
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Matrix Metalloproteinase 14/analysis
MH  - Matrix Metalloproteinase 2/*analysis
MH  - Matrix Metalloproteinase 9/*analysis
MH  - Middle Aged
MH  - Osteosarcoma/chemistry/*mortality
MH  - Prognosis
EDAT- 2014/02/01 06:00
MHDA- 2014/08/20 06:00
CRDT- 2014/02/01 06:00
PHST- 2013/12/25 00:00 [received]
PHST- 2014/01/17 00:00 [accepted]
PHST- 2014/02/01 06:00 [entrez]
PHST- 2014/02/01 06:00 [pubmed]
PHST- 2014/08/20 06:00 [medline]
AID - 10.1007/s13277-014-1668-8 [doi]
PST - ppublish
SO  - Tumour Biol. 2014 Jun;35(6):5159-65. doi: 10.1007/s13277-014-1668-8. Epub 2014 
      Jan 31.